Li Fu

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Venues

Biomedicines

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Dean Gilham, Sylwia Wasiak, Brooke D Rakai, Li Fu, Laura M Tsujikawa, Christopher D Sarsons, Agostina Carestia, Kenneth Lebioda, Jan O Johansson, Michael Sweeney, Kamyar Kalantar-Zadeh, Ewelina Kulikowski
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment. Biomedicines 11 (6) (2023)
Dean Gilham, Sylwia Wasiak, Brooke D Rakai, Li Fu, Laura M Tsujikawa, Christopher D Sarsons, Agostina Carestia, Kenneth Lebioda, Jan O Johansson, Michael Sweeney, Kamyar Kalantar-Zadeh, Ewelina Kulikowski
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment. Biomedicines 11 (6) (2023)
Li Fu, Sylwia Wasiak, Laura M Tsujikawa, Brooke D Rakai, Stephanie C Stotz, Norman C W Wong, Jan O Johansson, Michael Sweeney, Connie M Mohan, Aneal Khan, Ewelina Kulikowski
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy. Pharmacology research & perspectives 10 (3) (2022)
Dean Gilham, Audrey L Smith, Li Fu, Dalia Y Moore, Abenaya Muralidharan, St Patrick M Reid, Stephanie C Stotz, Jan O Johansson, Michael Sweeney, Norman C W Wong, Ewelina Kulikowski, Dalia El-Gamal
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro. Biomedicines 9 (4) (2021)

Li Fu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Li Fu